Unyango olutsha lwe-Advanced Prostate Cancer

A BAMBA FreeRelease | eTurboNews | eTN
IAvatar kaLinda Hohnholz
Ibhalwe ngu Linda Hohnholz

I-Accord BioPharma ibhengeze namhlanje, ngentsebenziswano ne-Foresee Pharmaceuticals Co., Ltd., ukuphehlelelwa kwe-US kweCAMCEVI™ (leuprolide) 42mg inaliti ye-emulsion yonyango lomhlaza wedlala lesinyi kubantu abadala. I-US Food and Drug Administration ivume iSicelo esitsha seChiza (i-NDA) se-CAMCEVI esivela kwi-Foresee Pharmaceuticals ngomhla wama-25 kuMeyi, 2021. Inaliti ye-CAMCEVI™ 42 mg inelayisensi eyodwa kuphela kwi-Accord BioPharma e-US yokuthengisa.

"Ukuqaliswa kwe-CAMCEVI yase-US kuqinisekisa ukubaluleka kobuchwephesha be-Foresee's Stabilized Injectable Formulation (SIF) ubuvulindlela kwaye linyathelo elibalulekileyo ekufezekiseni umsebenzi wethu wokuphucula umgangatho wokunyamekela," kusho uDkt Ben Chien, umsunguli kunye noSihlalo we-Foresee. Siyazi ukuba i-Accord BioPharma iyabelana kule njongo ibalulekileyo.

I-CAMCEVI yeyokuqala ngqa ukuba ilungele ukutofwa inzala ye-leuprolide mesylate yenaliti engaphantsi kwesikhumba esiza kwisirinji esele ifakwe ngaphambili ngaphandle kokuxubana okufunekayo. Kwileyibhile evulekileyo, isifundo sengalo eyodwa yabantu abadala be-137 abafumana i-42mg ye-CAMCEVI ngoSuku lwe-0 kunye neVeki ye-24, i-CAMCEVI yanikezela ukunyanzeliswa kwe-testosterone eqhubekayo kumanqanaba e-castrate emva kwesitofu sokuqala, ukusuka kwiVeki yesi-4 ukuya kwiVeki ye-48.1 i-CAMCEVI akufanele isetyenziswe izigulane ezine-hypersensitivity kwi-GnRH okanye i-GnRH analogs ngenxa ye-anaphylactic reactions ezinokwenzeka.1 Iimpendulo ezixhaphakileyo eziqhelekileyo (≥10%) ezenzeka ngexesha lokulandelwa kwexesha eliqhelekileyo leentsuku ze-336 zazishushu, i-hypertension, i-injection site reactions, izifo zendlela yokuphefumula ephezulu. , intlungu ye-musculoskeletal, ukudinwa, kunye neentlungu ekupheleni.1

“I-Accord Healthcare ibonelela ngeemveliso zamayeza ezisemgangathweni e-US ukusukela kwiminyaka yoo-2000. Ngobu bambiswano noForesee ekusungulweni kweCAMCEVI, sichulumancile ukuphehlelela ngokusesikweni i-Accord BioPharma egxininise kakhulu kumayeza akhethekileyo, okuya ngaphaya kwebhayoloji ukuzisa ukufikelela ngakumbi kumayeza akumgangatho ophezulu kwizigulana kulo lonke elase-US, ”utshilo uBinish. Chudgar, uSihlalo, i-Accord Healthcare kunye ne-Accord BioPharma.

"Itekhnoloji ye-Foresee ivumela ukuba sinikeze unyango kumhlaza we-prostate ophucukileyo osebenzayo kunye nokulungeleyo kubasebenzi, kunye nesirinji ezaliswe kwangaphambili ibonelela ngamalungiselelo alula akhokelela kumava aphuculweyo onyango kubasebenzi bezempilo," utshilo uChrys Kokino, uMongameli wase-US. I-BioPharma kwi-Accord BioPharma. "I-CAMCEVI iphawula umzekelo obalulekileyo wefilosofi yethu - ukuya ngaphaya kwebhayoloji - isebenza."

Ulwazi oluBalulekileyo loKhuseleko: I-CAMCEVI, njengezinye ii-agonists ze-GnRH, ibangela ukunyuka okwethutyana kumanqanaba e-serum ye-testosterone kwiveki yokuqala yonyango enokubangela ukuba iimpawu zibe zibi nakakhulu. Izigulane ezinezilonda ze-vertebral ze-metastatic kunye / okanye kunye nokuphazamiseka kwendlela yomchamo kufuneka ziqwalaselwe ngokukhawuleza kwiiveki ezimbalwa zokuqala zonyango. I-Hyperglycemia kunye nomngcipheko okhulayo wokuphuhlisa isifo sikashukela kuye kwabikwa kumadoda afumana i-GnRH agonists. Amanqanaba eglucose yegazi kufuneka abekwe esweni kwaye alawulwe ngokwenkqubo yeklinikhi yangoku. Ukunyuka kwengozi ye-myocardial infarction, ukufa kwentliziyo ngokukhawuleza, kunye ne-stroke kuye kwabikwa ngokubambisana nokusetyenziswa kwe-agonists ye-GnRH. Izigulane kufuneka zibekwe iliso kwi-cardiovascular disease kwaye ngokwenkqubo yeklinikhi yangoku. Unyango lokunciphisa i-Androgen lunokwandisa ixesha le-QT. Ukuxhatshazwa kuye kwabikwa kwizigulane ezifumana i-agonists ye-GnRH, njenge-CAMCEVI. Jonga amanqanaba e-serum e-testosterone emva kwesitofu se-CAMCEVI. Ngokusekwe kwiziphumo kwizifundo zezilwanyana kunye nendlela yokwenza, i-CAMCEVI inokubangela ingozi yomntwana xa ilawulwa kwabasetyhini abakhulelweyo. Ezona zixhaphakileyo (≥10%) ukusabela okungalunganga ngexesha lokulandelelwa okuphakathi kweentsuku ezingama-336 zazishushu, uxinezeleko lwegazi, ukuchaneka kwendawo yokutofa, usulelo lwendlela yokuphefumula ephezulu, iintlungu ze-musculoskeletal, ukudinwa, kunye neentlungu eziphelweni.

INTO ONOKUYITHATHA KWELI NQAKU:

  • Ngolu thelelwano no-Foresee ekusungulweni kwe-CAMCEVI, sinochulumanco ukuphehlelela ngokusesikweni i-Accord BioPharma egxininise kakhulu kumayeza akhethekileyo, okuya kudlula ngaphaya kwebhayoloji ukuzisa ukufikelela ngakumbi kumayeza akumgangatho ophezulu kwizigulana kulo lonke elase-U.
  • Kwileyibhile evulekileyo, isifundo sengalo enye yabantu abadala be-137 abafumene i-42mg ye-CAMCEVI ngoSuku lwe-0 kunye neVeki ye-24, i-CAMCEVI ibonelele ngokunyanzeliswa kwe-testosterone eqhubekayo kumanqanaba e-castrate emva kwesitofu sokuqala, ukusuka kwiVeki yesi-4 ukuya kwiVeki ye-48.
  • ukuphehlelelwa kweCAMCEVI kuqinisekisa ukubaluleka kobuchwephesha beForesee bobuvulindlela obuzinzileyo boKuqulunqwa kwetofu (SIF) kwaye linyathelo elikhulu lokufezekisa injongo yethu yokuphucula umgangatho wokhathalelo,”.

Malunga nombhali

IAvatar kaLinda Hohnholz

Linda Hohnholz

Umhleli oyintloko we eTurboNews esekwe kwi-eTN HQ.

Bhlisa
Yaziswe ngawo
guest
0 izimvo
Inline feedbacks
Jonga zonke izimvo
0
Ndingazithanda iingcinga zakho, nceda uphawule.x
Yabelana ku...